Omnicare acquires excelleRx for $269M

Omnicare has agreed to buy excelleRx for $269 million in a move aimed at absorbing the company's technology and call center for pharmaceutical services. Philadelphia-based excelleRx provides pharmaceutical products and care services for hospices.

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.